Castration Resistant Prostate Cancer Crpc Therapeutics Market Size And Share

  • Report Code : TIPRE00016400
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Principales conclusions et analyse des parts de marché des traitements contre le cancer de la prostate résistant à la castration (CRPC) d'ici 2025-2031

Buy Now

Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Report Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Scope and Analysis Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Size and Share

Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Report Analysis

Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market

  • CAGR (2023 - 2031)
    XX%
  • Market Size 2023
    US$ XX million
  • Market Size 2031
    US$ XX Million

Report Coverage

  • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
  • Key future trends
  • Detailed PEST/Porter’s Five Forces and SWOT analysis
  • Industry landscape and competition analysis & recent developments
  • Detailed company profiles
  • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments

Key Players

  • Bayer AG
  • AbbVie Inc.
  • Johnson and Johnson
  • Sanofi
  • Amgen Inc.
  • Novartis AG
  • OncoGenex Technologies Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc

Regional Overview

  • Amérique du Nord
  • Europe
  • Asie-Pacifique
  • Amérique du Sud et centrale
  • Moyen-Orient et Afrique

Market Segmentation

By Thérapie
  • chimiothérapie
  • hormonothérapie
  • immunothérapie
  • radiothérapie
By Voie d'administration
  • injectable
  • orale
By Canal de distribution
  • hôpitaux et pharmacies de détail
  • distribution en ligne
By Géographie
  • Amérique du Nord
  • Europe
  • Asie-Pacifique
  • Amérique du Sud et Centrale